Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how ...

BofA Securities 2025 Healthcare Conference May 14, 2025 1:00 PM ETCompany ParticipantsJeff Stewart - EVP and Chief ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

The siRNA technology has has the potential to enable sustained and precise messenger RNA silencing, regulating the expression ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...

AbbVie Inc. closed 15.13% below its 52-week high of $218.66, which the company reached on March 10th.

Small interfering RNA (siRNA) gained another vote of confidence, albeit back end-loaded, from big pharma as privately held ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best income stocks. Amid concerns over trade restrictions and a weakening economy, some investors ...